AroCell’s VD ger sin syn på företaget i en videointervju
February 13, 2019 06:00 ET | AroCell AB
AroCell publicerar idag ett kort videointervju med Michael Brobjer, VD, och hans reflektion på de första månaderna i ledningen. Videon finns tillgänglig via länk nedan, på bolagets hemsida och via...
AroCell launches new website
February 01, 2019 07:32 ET | AroCell AB
Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell. The website...
AroCell lanserar ny hemsida
February 01, 2019 07:32 ET | AroCell AB
Idag lanserar AroCell sin nya hemsida. Målet med den nya hemsidan är att underlätta för våra kunder, affärspartner och investerare att hitta relevant information om AroCell. Webbplatsen (
AroCell signs distribution agreement with Eurobio Scientific in France
December 20, 2018 02:00 ET | AroCell AB
AroCell AB (publ) announced today that a distribution agreement has been signed with the French company Eurobio Scientific, for distribution of AroCell TK 210 ELISA in France and Switzerland. AroCell...
AroCell tecknar distributörsavtal med Eurobio Scientific i Frankrike
December 20, 2018 02:00 ET | AroCell AB
Arocell tillkännager idag att ett distributionsavtal har tecknats med det franska företaget Eurobio Scientific, för distribution av AroCell TK 210 ELISA i Frankrike och Schweiz. AroCell TK 210 ELISA...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
August 24, 2018 07:50 ET | AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...
ERYTECH to Webcast Presentation at the Jefferies Global Healthcare Conference
May 30, 2018 01:30 ET | Erytech Pharma S.A.
LYON, France, May 30, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating...
ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
May 14, 2018 16:30 ET | Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting
April 10, 2018 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and...
eFFECTOR Announces Appointment of John W. Smither to its Board of Directors
March 23, 2018 14:00 ET | eFFECTOR Therapeutics
SAN DIEGO, March 23, 2018 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced the...